decorative image
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
decorative image
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
seed logo
small business image

[Omnibus Solicitations] [Specific Opportunities]

SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. 

NIH advertises the availability of grant support through notices of funding opportunities (NOFOs), previously referred to as funding opportunity announcements (FOAs).

Helpful Tips

Omnibus Solicitations (Parent Announcements)

Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These funding opportunities do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations.

Read the Program Descriptions and Research Topics to understand the awarding components, their topics of interest, and staff contacts. For topics that require additional funding to reach the marketplace, please refer to our list of SBA approved waiver eligible topics.

Standard Application Due Dates: September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays move to the next business day.

 

Notice of Information: Anticipated Publication of the PHS 2023-2 Omnibus Solicitations

We anticipate publishing the PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications in the summer of 2023. The expected first application due date will be September 5, 2023.

These notices of funding opportunities (NOFOs) will be a re-issuance of the following omnibus solicitations:

  • PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
  • PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
  • PA-22-179: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Please refer to the notice (NOT-OD-23-124) for more information. 


Specific Funding Opportunities

Some SBIR/STTR grant solicitations are focused on specific research areas. Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program.

Title NOFO/Notice Number Organization Release Date Due Date(s) Expiration Date Clinical Trials
Notice of Special Interest (NOSI): Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (SBIR/STTR) NOT-AT-21-001 NCCIH 10/23/2020 01/05/2024 Optional
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) PAR-21-114 NINDS 01/25/2021 Standard dates apply The first standard due date f...(see announcement for full details) 01/06/2024 Not Allowed
Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace NOT-MH-21-125 NIMHNIANIAAANIBIBNINDSNIDANEINCCIHNICHDNIDCD 03/03/2021 01/06/2024 Not Allowed
Notice of Special Interest (NOSI): Small Business Digital Technologies for Early Detection, Characterization and Monitoring of Senescence-Related Changes NOT-AG-23-004 NIA 02/07/2023 01/06/2026 Optional
Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes NOT-CA-21-031 NCINIA 01/27/2021 01/08/2024 Optional
Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability NOT-DC-21-001 NIDCD 02/16/2021 01/08/2024 Optional
Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition NOT-HD-21-027 NICHDNIAAANCINIMHNIAMSOBSSRNIBIBNIDCR 06/22/2021 01/08/2024 Optional
Notice of Special Interest: Biomarker Discover and Validation in Functional Neurological Disorders NOT-NS-22-010 NINDS 10/01/2021 01/08/2025 Optional
Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) NOT-NS-22-017 NINDSNIDCRNEINCINIA 11/12/2021 01/08/2025 Not Allowed
Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research NOT-AI-22-004 NIAIDNIAMSNCCIHNCI 11/23/2021 01/08/2025 Optional
Notice of Special Interest: Research on Pain, Pain Management, and Opioids in Aging NOT-AG-22-004 NIA 12/22/2021 01/08/2025 Optional
Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics NOT-AI-23-001 NIAIDNCINIBIB 11/23/2022 01/08/2026 Not Allowed
Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs) NOT-AI-23-013 NIAIDNIAMSNIMHNINDS 11/25/2022 01/08/2026 Optional
Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine NOT-AI-23-007 NIAID 11/25/2022 01/08/2026 Optional
Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application NOT-HG-21-018 NHGRI 12/04/2020 01/10/2024 Not Allowed
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) PAR-21-082 NIAID 01/14/2021 May 14, 2021; September 13, 2021; January 14, 2022...(see announcement for full details) 01/14/2024 Required
Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine NOT-AI-23-031 NIAID 02/23/2023 01/15/2026 Optional
Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities NOT-EY-22-004 NEINIMHD 02/14/2022 01/25/2025 Optional
Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration NOT-EY-22-002 NEI 01/10/2022 02/10/2025 Optional
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) RFA-DA-23-021 NIDA 03/28/2022 Multiple dates, see announcement....(see announcement for full details) 02/15/2025 Optional
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) RFA-DA-24-038 NIDA 04/18/2023 02/15/2025 Optional
Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research NOT-EY-23-005 NEI 04/03/2023 02/16/2026 Not Allowed
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) RFA-HL-23-008 NHLBINCATS 11/16/2021 02/29/2024 Optional
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) RFA-HL-23-009 NHLBI 11/16/2021 02/29/2024 Optional
Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research NOT-CA-22-037 NCINHLBINIANIDANIMHNINROBSSR 01/27/2022 03/09/2024 Optional
Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment NOT-EY-22-010 NEI 02/04/2022 03/09/2024 Optional
HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) RFA-NS-23-006 NINDSNCATSNCCIHNHLBINIANIAAANIAMSNICHDNIGMSNIMHORIP 09/15/2022 Multiple dates, see announcement....(see announcement for full details) 04/05/2025 Not Allowed
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) RFA-NS-23-007 NINDSNCATSNCCIHNCINHLBINIANIAAANIAMSNICHDNIGMSNIMHORIP 09/15/2022 Multiple dates, see announcement....(see announcement for full details) 04/05/2025 Not Allowed
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) PAR-21-265 NINDS 07/15/2021 Standard dates apply The first standard due date f...(see announcement for full details) 04/06/2024 Optional
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) PAR-21-266 NINDS 07/15/2021 Standard dates apply The first standard due date f...(see announcement for full details) 04/06/2024 Required
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required) PAR-21-267 NINDS 07/16/2021 Standard dates apply The first standard due date f...(see announcement for full details) 04/06/2024 Required
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) PAR-21-233 NINDSNIAAANIANCCIHNICHDNIBIBNIMHOBSSRNIDCRNIDANEI 04/23/2021 August 10, 2021, February 9, 2022, August 9, 2022,...(see announcement for full details) 04/06/2024 Optional
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) PAR-21-224 NINDS 05/05/2021 Standard dates apply *** Note new SBIR/STTR Standa...(see announcement for full details) 04/06/2024 Optional
Notice of Special Interest: NIDCD Health Disparities and Inequities Research NOT-DC-21-003 NIDCDSGMRO 06/11/2021 05/08/2024 Optional
Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies NOT-AI-21-056 NIAIDNIDA 06/17/2021 05/08/2024 Not Allowed
Notice of Special Interest (NOSI): Advancing Innovative Non-invasive Physiologic Monitoring To Improve Fetal Assessment NOT-HD-21-053 NICHD 12/28/2021 05/08/2024 Optional
Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging NOT-EB-22-006 NIBIB 03/21/2022 05/08/2024 Optional
Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection NOT-AI-22-043 NIAID 04/29/2022 05/08/2025 Not Allowed
Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services NOT-MH-22-110 NIMHNIDAORWH 02/08/2022 05/08/2025 Optional
Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications. NOT-EB-23-002 NIBIBNCCIHNCINHLBINIANIAIDNICHDNIGMS 04/14/2023 05/17/2026 Optional
Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism NOT-DC-23-009 NIDCD 04/03/2023 06/06/2026 Optional
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed) PAR-23-267 NCATS 04/18/2023 Multiple dates, see announcement....(see announcement for full details) 06/07/2025 Not Allowed
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed PAR-23-268 NCATS 04/18/2023 06/07/2025 Not Allowed
Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health NOT-OD-21-100 OBSSRNIMHDNIDANIMHORWHNIDCDSGMROODPNIANHLBINCININRNCCIHNEINICHD 04/08/2021 06/08/2024 Optional
Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed) PAR-21-247 NHGRINIAIDNCI 07/12/2021 October 1, 2021; June 15, 2022; June 15, 2023 All...(see announcement for full details) 06/16/2023 Not Allowed
Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) PAR-21-282 NIDANIMHNEINIDCRNIAOBSSRNCCIHNIBIBNICHDNIAAANINDS 08/20/2021 October 20, 2021; February 18, 2022; June 20, 2022...(see announcement for full details) 06/21/2024 Optional
Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech NOT-NS-22-052 NINDSNIAAANIBIBNCCIHNEINIANICHDOBSSRNIDCDNIDANIMH 01/05/2022 06/21/2024 Optional
Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech NOT-NS-23-002 NINDSNCCIHNCINEINIANIAAANIAMSNICHDNIDANIDCRNIMH 08/03/2022 06/21/2024 Optional
Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) NOT-NS-23-062 NINDS 02/06/2023 06/24/2023 Optional
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers NOT-CA-23-004 NCI 10/17/2022 07/02/2025 Optional
Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) RFA-ES-23-008 NIEHS 03/21/2023 07/08/2023 Not Allowed
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) RFA-TR-22-029 NCATS 07/13/2022 07/13/2023 Required
SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed) RFA-ES-23-005 NIEHS 03/06/2023 July 14, 2023...(see announcement for full details) 07/15/2023 Not Allowed
Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches NOT-DE-20-006 NIDCR 06/05/2020 08/08/2023 Not Allowed
Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (UT1, UT2 Clinical Trail Not Allowed) RFA-TR-22-031 NCATSNINDS 09/19/2022 Multiple dates, see announcement....(see announcement for full details) 08/22/2023 Not Allowed
Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed) RFA-TR-22-032 NCATSNINDS 09/19/2022 Multiple dates, see announcement....(see announcement for full details) 08/22/2023 Not Allowed
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) RFA-CA-23-034 NCI 04/21/2023 Not Applicable...(see announcement for full details) 08/22/2023 Optional
Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) RFA-CA-23-035 NCINHGRINIBIBNIDA 04/21/2023 August 21, 2023...(see announcement for full details) 08/22/2023 Not Allowed
Notice of Special Interest: Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) NOT-AG-22-032 NIA 09/28/2022 09/05/2025 Optional
Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) NOT-DE-21-012 NIDCR 09/01/2021 09/05/2025 Not Allowed
Notice of Special Interest (NOSI): Methods Development in Natural Products Research (SBIR/STTR) NOT-AT-20-015 NCCIH 07/16/2020 09/06/2023 Not Allowed
Notice of Special Interest: Kidney Precision Medicine Technology Development and Translation NOT-DK-21-007 NIDDK 12/02/2020 09/06/2023 Optional
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) PAR-21-225 ORIP 04/30/2021 Standard dates apply The first standard due date f...(see announcement for full details) 09/06/2024 Not Allowed
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) PAR-21-226 ORIP 04/30/2021 Standard dates apply The first standard due date f...(see announcement for full details) 09/06/2024 Not Allowed
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) PAS-22-196 NIANINDS 06/21/2022 09/06/2025 Optional
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) PAS-22-197 NIANINDS 06/21/2022 09/06/2025 Optional
Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) PAR-23-032 NIAMS 10/26/2022 09/06/2025 Not Allowed
HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) PAR-23-069 NINDSNCATSNCCIHNEINIAMS 01/03/2023 09/06/2025 Not Allowed
Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) RFA-MD-23-002 NIMHDNCATSNIDCRNINDS 01/30/2023 09/07/2023 Optional
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) RFA-MD-23-003 NIMHDNCATSNHLBINIANIAAANIBIBNIDCRNIDDKNINDS 01/30/2023 09/07/2023 Optional
Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings NOT-CA-21-062 NCI 07/23/2021 09/07/2024 Optional
Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings NOT-MH-21-230 NIMHNIDA 04/16/2021 09/08/2023 Optional
Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) PAR-21-059 NINDS 11/19/2020 March 15, 2021, June 22, 2021, February 22, 2022, ...(see announcement for full details) 09/08/2023 Optional
Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) PAR-21-057 NINDS 11/19/2020 February 22, 2021, June 22, 2021, February 22, 202...(see announcement for full details) 09/08/2023 Optional
Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) NOT-HL-23-066 NHLBI 01/31/2023 09/08/2026 Optional
Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults NOT-MH-23-250 NIMH 05/19/2023 09/08/2026 Optional
Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College NOT-AA-22-001 NIAAA 12/09/2021 09/09/2025 Optional
Notice of Special Interest: NIGMS Priorities for Small Business Development of Sepsis Diagnostics and Therapeutics NOT-GM-20-028 NIGMS 06/02/2020 09/12/2023 Optional
Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease NOT-HG-22-007 NHGRI 12/09/2021 11/05/2024 Not Allowed
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R41/R42 Clinical Trial Optional) RFA-DA-24-017 NIDA 05/23/2023 11/10/2023 Optional
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) RFA-DA-24-018 NIDA 05/23/2023 11/11/2023 Optional
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) PAR-22-102 NIAAA 01/21/2022 Multiple dates, see announcement....(see announcement for full details) 12/05/2024 Optional
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) PAR-22-103 NIAAA 01/21/2022 Multiple dates, see announcement....(see announcement for full details) 12/05/2024 Optional
Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed) PAR-21-297 NICHDNIAIDNIMH 08/31/2021 Only accepting applications for the AIDS Applicati...(see announcement for full details) 12/10/2023 Not Allowed
Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed) PAR-21-298 NICHDNIMH 08/31/2021 Only accepting applications for the AIDS Applicati...(see announcement for full details) 12/10/2023 Not Allowed
Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA) NOT-GM-23-015 NIGMSNLMODSS 12/14/2022 12/19/2025 Optional
Notice of Special Interest (NOSI): Genomics Education Interactive Digital Media Resources (SBIR/STTR) NOT-HG-21-038 NHGRI 08/26/2021 12/31/2024 Not Allowed
Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information NOT-HG-22-011 NHGRI 01/06/2022 12/31/2025 Optional